Skip to main content

Table 1 Baseline characteristics

From: Effects of three frequencies of self-monitored blood glucose on HbA1c and quality of life in patients with type 2 diabetes with once daily insulin and stable control: a randomized trial

  A: SMBG 1 day weekly
(n = 22)
B: SMBG 1 day every 2 weeks
(n = 16)
C: SMBG 1 day monthly
(n = 20)
Gender (male) 13 (59) 8 (50) 12 (60)
Age (years) 67 ± 12 69 ± 9 65 ± 9
Diabetes duration (year) 11 (6, 15) 8 (6, 13) 13 (7, 17)
Duration SMBG (year) 4 (2, 7) 4 (3, 7) 5 (4, 6)
HbA1c (mmol/mol) 51 ± 4.7 52 ± 4.6 51 ± 5.6
Fasting blood glucose (mmol/L) 6.7 (6.0, 7.2) 5.9 (4.8, 6.4) 6.5 (5.4, 8.2)
Dose of insulin (units) 22 (16) 30 (22) 20 (15)
Metformin 21 (95%) 14 (88%) 16 (80%)
Tolbutamide 4 (18%) 4 (25%) 7 (35%)
Gliclazide 5 (23%) 4 (25%) 3 (15%)
Glimepiride 3 (14%) 2 (13%) 3 (15%)
Body mass index (kg/m2) 30 ± 4.1 30 ± 2.8 30 ± 3.6
Systolic blood pressure (mmHg) 141 ± 14 134 ± 11 133 ± 16
Cholesterol/HDL ratio 3.30 (2.9, 4.0) 3.60 (3.3, 4.3) 3.40 (2.8, 4.4)
Macrovascular complication (yes) 5 (23) 6 (38) 5 (25)
Serum creatinine (μmol/L) 71 (63) 73 (60, 97) 76 (63, 82)
Albumin creatinine ratio 1.0 (0.3, 2.0) 1.6 (0.99, 4.8) 0.8 (0.5, 2.3)
Retinopathy (yes) 0 (0) 1 (6) 3 (15)
Dose of insulin (units) 22 (16, 29) 30 (22, 36) 20 (15, 39)
Smoking (yes) 4 (18) 2 (13) 3 (15)
Alcohol use (yes) 12 (55) 6 (38) 10 (50)
  1. Data are mean ± SD, n (% of known data) or median (P25, P75)